-
公开(公告)号：US20140271692A1
公开(公告)日：2014-09-18
申请号：US14138421
申请日：2013-12-23
发明人： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver SCHOOR , Claudia TRAUTWEIN
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。
-
公开(公告)号：US20230192886A1
公开(公告)日：2023-06-22
申请号：US18053705
申请日：2022-11-08
发明人： Harpreet SINGH , Toni WEINSCHENK , Steffen WALTER
CPC分类号： C07K16/3053 , A61K38/1774 , A61P35/00
摘要： A method of treating a patient who has a recurrent cancer that presents a peptide, including administering to the patient a treatment composition comprising an antigen binding molecule that binds to the peptide, in which the patient has received a prior treatment with a pretreatment composition comprising a second antigen binding molecule that binds to a different peptide.
-
公开(公告)号：US20220362363A1
公开(公告)日：2022-11-17
申请号：US17852207
申请日：2022-06-28
发明人： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC分类号： A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20220362362A1
公开(公告)日：2022-11-17
申请号：US17852205
申请日：2022-06-28
发明人： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC分类号： A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
15.发明申请公开(公告)号：US20220016207A1
公开(公告)日：2022-01-20
申请号：US17484703
申请日：2021-09-24
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US20210393754A1
公开(公告)日：2021-12-23
申请号：US17390584
申请日：2021-07-30
发明人： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC分类号： A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
17.发明申请公开(公告)号：US20210275634A1
公开(公告)日：2021-09-09
申请号：US17327116
申请日：2021-05-21
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US20210261614A1
公开(公告)日：2021-08-26
申请号：US17238787
申请日：2021-04-23
发明人： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC分类号： C07K7/06 , A61K39/00 , C07K7/08 , A61K35/17 , G01N33/574 , C07K14/74 , A61M5/00 , C12N5/0783
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
19.发明申请公开(公告)号：US20210260160A1
公开(公告)日：2021-08-26
申请号：US17238943
申请日：2021-04-23
摘要： A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US20190322703A1
公开(公告)日：2019-10-24
申请号：US16444693
申请日：2019-06-18
发明人： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
摘要： A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.028 秒)
